ESR1 and breast neoplasm: We then established an in vivo reporter system, which allows the evaluation of ER signaling in breast tumors that are treated with or without dox to knockout Rad51b. Inducible cells with ERE-luciferase reporter were injected into mice with mammary fat pad implantation.